MAUI Imaging Transforms Diagnostics: $14M Fuels Breakthrough Ultrasound Rollout
July 31, 2025, 9:36 am
MAUI Imaging, a San Jose innovator, just secured $14 million in Series D funding. This significant capital influx will accelerate production, sales, and marketing for their groundbreaking Computed Echo Tomography (CET) ultrasound technology. CET uniquely visualizes internal anatomy, overcoming traditional ultrasound barriers like bone and gas. Its patented algorithms create detailed, CT-like images without harmful radiation. The FDA-cleared MAUI K3900 system is now available commercially. It revolutionizes imaging for trauma, neurosurgery, and general diagnostics. This technology promises faster, more accurate insights, improving patient outcomes across diverse clinical settings and expanding ultrasound's crucial role in medical care, including military applications.
A significant shift is underway in medical imaging. MAUI Imaging has secured $14 million in Series D funding. This capital will accelerate the production, sales, and marketing of its innovative technology. The company focuses on its patented Computed Echo Tomography (CET) ultrasound system. This system offers unprecedented views inside the human body.
Traditional ultrasound faces limits. Bone, gas, and implants often obscure vital structures. MAUI’s CET technology overcomes these long-standing barriers. It provides clear images where other systems fail. This includes difficult-to-image areas like the lung and cranium. Its unique approach means more comprehensive diagnostic information is available.
The MAUI K3900 device received 510(k) FDA clearance in October 2023. This critical milestone cleared the path for commercial use. The system is now available to healthcare providers. Initial deliveries are underway, marking a new era for diagnostic capabilities. Acertara Acoustic Laboratories leads the Series D round. It also serves as MAUI Imaging’s exclusive U.S. distributorship for hospitals.
Computed Echo Tomography operates differently. It “pings” the designated body part. It then processes reflected energy from various paths. Proprietary patented algorithms combine this data. This creates a reliable image of all structures below the probe. It’s a cross between ultrasound and CT scanning. Crucially, it uses no dangerous ionizing radiation. This offers a safer alternative for frequent imaging needs.
The technology processes trillions of calculations per second. This remarkable speed is possible due to modern chip advancements. The system generates massive datasets. These are much larger than traditional ultrasound data. They can be sliced into countless images, similar to CT scans. This allows for deeper analytics and more profound anatomical insights. Such volumetric imaging expands ultrasound’s role significantly, especially in AI-driven diagnostics.
MAUI Imaging emerged from stealth in August 2024. This was marked by a $4 million U.S. Department of Defense contract. The contract supports trauma medicine. It aims to improve diagnosis and interventional care. This is vital in high-volume or mass-casualty events. It is also crucial in resource-limited environments. The program operates at the University of Maryland Shock Trauma Center in Baltimore. This facility trains military healthcare providers. The technology’s portability and effectiveness make it ideal for such critical scenarios.
The MAUI K3900 Ultrasound Imaging System is versatile. It is intended for use across many applications. These include Fetal, Abdominal, Cardiac, Musculo-skeletal, Urology, and Intraoperative uses. Its differentiating images show great promise in trauma, neurosurgery, and interventional radiology. For instance, rapid imaging of the brain is possible. Other internal organs and structures can be viewed in real-time. Existing clinical personnel can operate the system without additional training. This ease of use enhances its utility in busy clinical settings.
The company holds an impressive patent portfolio. It includes over 160 granted patents. Dozens more are pending, both domestically and internationally. These patents protect its core innovations. They specifically address speed-of-sound aberration issues in tissue. This enables views of previously unobtainable tissue types.
The impact on patient outcomes is profound. Faster, more accurate diagnoses lead to quicker interventions. This can save lives. It can improve recovery rates. Expanding ultrasound’s reach reduces reliance on more expensive or invasive imaging methods. The technology democratizes advanced medical imaging. It makes it accessible in more settings.
The partnership with Acertara Acoustic Laboratories is strategic. Acertara is a leader in acoustic measurements and medical device testing. Their distribution network will accelerate adoption in hospitals nationwide. This collaboration ensures the MAUI K3900 reaches critical care facilities efficiently. The focus remains on improving patient care through superior diagnostic tools.
MAUI Imaging’s breakthrough represents a major advancement. It expands ultrasound’s capabilities. It simplifies image acquisition. It makes sophisticated diagnostics more intuitive. This innovation is set to redefine medical imaging standards. It will empower clinicians with unprecedented visual information. This ultimately leads to better, faster decisions for patients in dire need. The future of diagnostic imaging looks clearer than ever.
A significant shift is underway in medical imaging. MAUI Imaging has secured $14 million in Series D funding. This capital will accelerate the production, sales, and marketing of its innovative technology. The company focuses on its patented Computed Echo Tomography (CET) ultrasound system. This system offers unprecedented views inside the human body.
Traditional ultrasound faces limits. Bone, gas, and implants often obscure vital structures. MAUI’s CET technology overcomes these long-standing barriers. It provides clear images where other systems fail. This includes difficult-to-image areas like the lung and cranium. Its unique approach means more comprehensive diagnostic information is available.
The MAUI K3900 device received 510(k) FDA clearance in October 2023. This critical milestone cleared the path for commercial use. The system is now available to healthcare providers. Initial deliveries are underway, marking a new era for diagnostic capabilities. Acertara Acoustic Laboratories leads the Series D round. It also serves as MAUI Imaging’s exclusive U.S. distributorship for hospitals.
Computed Echo Tomography operates differently. It “pings” the designated body part. It then processes reflected energy from various paths. Proprietary patented algorithms combine this data. This creates a reliable image of all structures below the probe. It’s a cross between ultrasound and CT scanning. Crucially, it uses no dangerous ionizing radiation. This offers a safer alternative for frequent imaging needs.
The technology processes trillions of calculations per second. This remarkable speed is possible due to modern chip advancements. The system generates massive datasets. These are much larger than traditional ultrasound data. They can be sliced into countless images, similar to CT scans. This allows for deeper analytics and more profound anatomical insights. Such volumetric imaging expands ultrasound’s role significantly, especially in AI-driven diagnostics.
MAUI Imaging emerged from stealth in August 2024. This was marked by a $4 million U.S. Department of Defense contract. The contract supports trauma medicine. It aims to improve diagnosis and interventional care. This is vital in high-volume or mass-casualty events. It is also crucial in resource-limited environments. The program operates at the University of Maryland Shock Trauma Center in Baltimore. This facility trains military healthcare providers. The technology’s portability and effectiveness make it ideal for such critical scenarios.
The MAUI K3900 Ultrasound Imaging System is versatile. It is intended for use across many applications. These include Fetal, Abdominal, Cardiac, Musculo-skeletal, Urology, and Intraoperative uses. Its differentiating images show great promise in trauma, neurosurgery, and interventional radiology. For instance, rapid imaging of the brain is possible. Other internal organs and structures can be viewed in real-time. Existing clinical personnel can operate the system without additional training. This ease of use enhances its utility in busy clinical settings.
The company holds an impressive patent portfolio. It includes over 160 granted patents. Dozens more are pending, both domestically and internationally. These patents protect its core innovations. They specifically address speed-of-sound aberration issues in tissue. This enables views of previously unobtainable tissue types.
The impact on patient outcomes is profound. Faster, more accurate diagnoses lead to quicker interventions. This can save lives. It can improve recovery rates. Expanding ultrasound’s reach reduces reliance on more expensive or invasive imaging methods. The technology democratizes advanced medical imaging. It makes it accessible in more settings.
The partnership with Acertara Acoustic Laboratories is strategic. Acertara is a leader in acoustic measurements and medical device testing. Their distribution network will accelerate adoption in hospitals nationwide. This collaboration ensures the MAUI K3900 reaches critical care facilities efficiently. The focus remains on improving patient care through superior diagnostic tools.
MAUI Imaging’s breakthrough represents a major advancement. It expands ultrasound’s capabilities. It simplifies image acquisition. It makes sophisticated diagnostics more intuitive. This innovation is set to redefine medical imaging standards. It will empower clinicians with unprecedented visual information. This ultimately leads to better, faster decisions for patients in dire need. The future of diagnostic imaging looks clearer than ever.